HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Expression and predictive value of lymph-specific markers in urothelial carcinoma of the bladder.

AbstractOBJECTIVE:
To evaluate the expression of multiple lymph-specific markers and to test its association with histopathological characteristics and clinical outcomes in patients with urothelial carcinoma of the bladder (UCB) treated by radical cystectomy (RC).
PATIENTS AND METHODS:
Vascular endothelial growth factor-C and -D (VEGF-C/-D), its receptor VEGF receptor-3 (VEGFR-3), and chemokine receptor type 7 (CCR7) expressions were assessed by immunohistochemistry in RC specimens of 119 patients. Semiquantitative analyses of marker expressions were correlated with clinical and pathological characteristics. Univariable and multivariable analyses were performed to identify predictors of disease-specific survival (DSS) and recurrence free survival (RFS).
RESULTS:
VEGF-C, VEGF-D, VEGFR-3, and CCR7 were overexpressed in 37.8%, 26.2%, 50.4%, and 23.5% of UCB samples, respectively. VEGF-D overexpression was significantly associated with a positive lymph node status (pN+). On univariable analysis, a higher pT stage, pN+, the presence of lymphovascular invasion (LVI) and vascular invasion (VI) (all P<0.001), and overexpressions of VEGF-D (P = 0.049) and VEGFR-3 (P = 0.032) were significantly associated with reduced DSS. On multivariable analysis, pT stage (P = 0.002) and pN+status (P = 0.009) were identified as independent predictors of reduced DSS. In a subgroup of patients without lymph node metastasis (pN0; n = 75), pT stage (P = 0.043) and VEGFR-3 overexpression (P = 0.008) were independent predictors of reduced DSS.
CONCLUSION:
Lymph-specific markers are frequently overexpressed in UCB. VEGF-D overexpression is associated with the presence of lymphatic metastasis. In patients without lymph node metastasis at the time of RC, an assessment of VEGFR-3 expression may improve the identification of high-risk patients. These findings require prospective validation to determine the potential benefit of more aggressive adjuvant treatment.
AuthorsJost von Hardenberg, Thomas Martini, Antje Knauer, Philipp Ströbel, Andreas Becker, Edwin Herrmann, Charlotte Schubert, Annette Steidler, Christian Bolenz
JournalUrologic oncology (Urol Oncol) Vol. 32 Issue 1 Pg. 54.e9-17 (Jan 2014) ISSN: 1873-2496 [Electronic] United States
PMID24360666 (Publication Type: Journal Article)
Copyright© 2013 Published by Elsevier Inc.
Chemical References
  • Biomarkers, Tumor
  • CCR7 protein, human
  • Receptors, CCR7
  • Vascular Endothelial Growth Factor C
  • Vascular Endothelial Growth Factor D
  • FLT4 protein, human
  • Vascular Endothelial Growth Factor Receptor-3
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor (biosynthesis)
  • Carcinoma, Transitional Cell (diagnosis, metabolism, surgery)
  • Cystectomy (methods)
  • Female
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Lymphatic Metastasis
  • Lymphatic System (metabolism)
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Recurrence, Local
  • Predictive Value of Tests
  • Prognosis
  • Receptors, CCR7 (biosynthesis)
  • Urinary Bladder Neoplasms (diagnosis, metabolism, surgery)
  • Vascular Endothelial Growth Factor C (biosynthesis)
  • Vascular Endothelial Growth Factor D (biosynthesis)
  • Vascular Endothelial Growth Factor Receptor-3 (biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: